Latest Conference Articles

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Patients with prostate cancer have to be approached differently depending on the state of their metastases.

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.

The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.

Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what is still needed to be investigated in the future following the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what some of the most important findings were in regard to patient outcomes from the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses findings regarding adverse events during the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses his presentation on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses patients reports of their quality of life while being treated with lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how results from the phase 3 trial could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.

Researchers estimate a 5-year overall survival rate of 42.9% for patients treated with durvalumab compared with 33.4% for those administered a placebo after chemoradiation therapy.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

In PD-L1-positive patients, tislelizumab improved median overall survival by 3.5 months with a 46% decrease in the risk of death compared with chemotherapy.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, detailed some of the AEs experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib.

Results from the phase 3 TITAN study shows a combination therapy that includes apalutamide may achieve survival benefit without significant burden of adverse effects.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.